ILARIS canakinumab 150 mg powder for injection

Šalis: Australija

kalba: anglų

Šaltinis: Department of Health (Therapeutic Goods Administration)

Veiklioji medžiaga:

Canakinumab, Quantity: 150 mg

Prieinama:

Novartis Pharmaceuticals Australia Pty Ltd

INN (Tarptautinis Pavadinimas):

Canakinumab

Vaisto forma:

Injection, powder for

Sudėtis:

Excipient Ingredients: sucrose; histidine; histidine hydrochloride monohydrate; polysorbate 80; dilute hydrochloric acid

Vartojimo būdas:

Subcutaneous

Vienetai pakuotėje:

1, 4

Recepto tipas:

(S4) Prescription Only Medicine

Terapinės indikacijos:

Ilaris is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 2 years or older including: Familial Cold Autoinflammatory Syndrome (FCAS) /Familial Cold Urticaria (FCU); Muckle-Wells Syndrome (MWS); Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). Ilaris is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years or older.

Produkto santrauka:

Visual Identification: White solid lyophilisate; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius

Autorizacija statusas:

Registered

Leidimo data:

2010-05-10